Constipation - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 91 pages report, published by Global Markets Direct

Keywords : Constipation Therapeutic Products under Development, Key Players in Constipation Therapeutics, Constipation Pipeline Overview, Constipation Pipeline, Constipation Pipeline Assessment

Report ThumbnailSeptember-2013
Constipation - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Constipation - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Constipation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Constipation. Constipation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Constipation.
- A review of the Constipation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Constipation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Constipation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Constipation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Constipation, H2 2013 9
  • Products under Development for Constipation - Comparative Analysis, H2 2013 10
  • Products under Development by Companies, H2 2013 11
  • Products under Investigation by Universities/Institutes, H2 2013 13
  • Late Stage Products, H2 2013 14
  • Mid Clinical Stage Products, H2 2013 15
  • Early Clinical Stage Products, H2 2013 16
  • Discovery and Pre-Clinical Stage Products, H2 2013 17
  • Assessment by Monotherapy Products, H2 2013 38
  • Assessment by Route of Administration, H2 2013 39
  • Assessment by Stage and Route of Administration, H2 2013 40
  • Assessment by Molecule Type, H2 2013 41
  • Assessment by Stage and Molecule Type, H2 2013 42
  • List of Tables
  • Number of Products Under Development for Constipation, H2 2013 9
  • Products under Development for Constipation - Comparative Analysis, H2 2013 10
  • Number of Products under Development by Companies, H2 2013 12
  • Number of Products under Investigation by Universities/Institutes, H2 2013 13
  • Comparative Analysis by Late Stage Development, H2 2013 14
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 15
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 16
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 17
  • Products under Development by Companies, H2 2013 18
  • Products under Investigation by Universities/Institutes, H2 2013 19
  • AstraZeneca PLC, H2 2013 20
  • Dainippon Sumitomo Pharma Co., Ltd., H2 2013 21
  • Astellas Pharma Inc., H2 2013 22
  • Dong-A Pharmaceutical Co., Ltd., H2 2013 23
  • Kissei Pharmaceutical Co., Ltd., H2 2013 24
  • Shire Plc, H2 2013 25
  • ARYx Therapeutics, H2 2013 26
  • Yuhan Corporation, H2 2013 27
  • Theravance, Inc., H2 2013 28
  • Sucampo Pharmaceuticals, Inc., H2 2013 29
  • Ironwood Pharmaceuticals, Inc., H2 2013 30
  • Synergy Pharmaceuticals, Inc., H2 2013 31
  • Braintree Laboratories, Inc., H2 2013 32
  • SunTen Phytotech Co., Ltd., H2 2013 33
  • Ferring Pharmaceuticals, Inc., H2 2013 34
  • MicroDose Therapeutx, Inc., H2 2013 35
  • Beech Tree Labs, Inc., H2 2013 36
  • Rhythm Pharmaceuticals, H2 2013 37
  • Assessment by Monotherapy Products, H2 2013 38
  • Assessment by Stage and Route of Administration, H2 2013 40
  • Assessment by Stage and Molecule Type, H2 2013 42
  • Constipation Therapeutics - Drug Profile Updates 68
  • Constipation Therapeutics - Dormant Products 81
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Constipation Overview 8
  • Therapeutics Development 9
  • An Overview of Pipeline Products for Constipation 9
  • Constipation Therapeutics under Development by Companies 11
  • Constipation Therapeutics under Investigation by Universities/Institutes 13
  • Late Stage Products 14
  • Comparative Analysis 14
  • Mid Clinical Stage Products 15
  • Comparative Analysis 15
  • Early Clinical Stage Products 16
  • Comparative Analysis 16
  • Discovery and Pre-Clinical Stage Products 17
  • Comparative Analysis 17
  • Constipation Therapeutics - Products under Development by Companies 18
  • Constipation Therapeutics - Products under Investigation by Universities/Institutes 19
  • Companies Involved in Constipation Therapeutics Development 20
  • AstraZeneca PLC 20
  • Dainippon Sumitomo Pharma Co., Ltd. 21
  • Astellas Pharma Inc. 22
  • Dong-A Pharmaceutical Co., Ltd. 23
  • Kissei Pharmaceutical Co., Ltd. 24
  • Shire Plc 25
  • ARYx Therapeutics 26
  • Yuhan Corporation 27
  • Theravance, Inc. 28
  • Sucampo Pharmaceuticals, Inc. 29
  • Ironwood Pharmaceuticals, Inc. 30
  • Synergy Pharmaceuticals, Inc. 31
  • Braintree Laboratories, Inc. 32
  • SunTen Phytotech Co., Ltd. 33
  • Ferring Pharmaceuticals, Inc. 34
  • MicroDose Therapeutx, Inc. 35
  • Beech Tree Labs, Inc. 36
  • Rhythm Pharmaceuticals 37
  • Constipation - Therapeutics Assessment 38
  • Assessment by Monotherapy Products 38
  • Assessment by Route of Administration 39
  • Assessment by Molecule Type 41
  • Drug Profiles 43
  • RM-131 - Drug Profile 43
  • Product Description 43
  • Mechanism of Action 43
  • R&D Progress 43
  • naronapride - Drug Profile 45
  • Product Description 45
  • Mechanism of Action 45
  • R&D Progress 45
  • prucalopride succinate - Drug Profile 47
  • Product Description 47
  • Mechanism of Action 47
  • R&D Progress 47
  • linaclotide - Drug Profile 49
  • Product Description 49
  • Mechanism of Action 49
  • R&D Progress 49
  • lubiprostone - Drug Profile 51
  • Product Description 51
  • Mechanism of Action 51
  • R&D Progress 51
  • MDT-006 - Drug Profile 53
  • Product Description 53
  • Mechanism of Action 53
  • R&D Progress 53
  • velusetrag - Drug Profile 54
  • Product Description 54
  • Mechanism of Action 54
  • R&D Progress 54
  • YKP-10811 - Drug Profile 55
  • Product Description 55
  • Mechanism of Action 55
  • R&D Progress 55
  • elobixibat - Drug Profile 56
  • Product Description 56
  • Mechanism of Action 56
  • R&D Progress 56
  • Drug For Chronic Constipation - Drug Profile 57
  • Product Description 57
  • Mechanism of Action 57
  • R&D Progress 57
  • DA-6886 - Drug Profile 58
  • Product Description 58
  • Mechanism of Action 58
  • R&D Progress 58
  • BLI-801 - Drug Profile 59
  • Product Description 59
  • Mechanism of Action 59
  • R&D Progress 59
  • AZD-1722 - Drug Profile 60
  • Product Description 60
  • Mechanism of Action 60
  • R&D Progress 60
  • YH-12852 - Drug Profile 62
  • Product Description 62
  • Mechanism of Action 62
  • R&D Progress 62
  • DSP-6952 - Drug Profile 63
  • Product Description 63
  • Mechanism of Action 63
  • R&D Progress 63
  • KWA-0711 - Drug Profile 64
  • Product Description 64
  • Mechanism of Action 64
  • R&D Progress 64
  • mexiletine hydrochloride - Drug Profile 65
  • Product Description 65
  • Mechanism of Action 65
  • R&D Progress 65
  • ASP-7663 - Drug Profile 66
  • Product Description 66
  • Mechanism of Action 66
  • R&D Progress 66
  • 5-BOIP - Drug Profile 67
  • Product Description 67
  • Mechanism of Action 67
  • R&D Progress 67
  • Constipation Therapeutics - Drug Profile Updates 68
  • Constipation Therapeutics - Dormant Products 81
  • Constipation - Product Development Milestones 82
  • Featured News & Press Releases 82
  • Aug 05, 2013: Synergy Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA for Plecanatide in Chronic Idiopathic Constipation 82
  • Jun 13, 2013: Almirall And Ironwood Pharma Launch Constella For Treatments Of Adults Suffering From Moderate To Severe IBS-C In Europe 82
  • Jun 05, 2013: RaQualia Submits Summary Of Clinical Trial Report To MHRA For Phase I Study With RQ-00000010 83
  • May 21, 2013: Synergy Pharma Presents Plecanatide Results From Large Multicenter Clinical Study At Digestive Disease Week 2013 84
  • May 14, 2013: Ironwood Pharma And Forest Labs To Present Linaclotide Data At Digestive Disease Week 2013 85
  • May 02, 2013: Ferring Pharma Begins Phase III Trials Of Elobixibat For Chronic Idiopathic Constipation 86
  • Apr 23, 2013: Sucampo Pharma And Takeda Announce FDA Approval For Supplemental New Drug Application Of Amitiza 87
  • Apr 16, 2013: Rhythm Pharma Initiates Phase II Clinical Trial Of Ghrelin Prokinetic RM-131 For Lower GI Functional Disorders 87
  • Mar 15, 2013: Synergy Pharma To Present Study Results From Plecanatide Phase IIb/III Trial At Digestive Disease Week 2013 88
  • Mar 08, 2013: CordenPharma Colorado Named Approved Peptide Supplier for Linaclotide 88
  • Appendix 90
  • Methodology 90
  • Coverage 90
  • Secondary Research 90
  • Primary Research 90
  • Expert Panel Validation 90
  • Contact Us 91
  • Disclaimer 91

Please select a license type

Share

Related Products

Global Markets DirectConstipation - Pipeline Review, H2 2013Product ThumbnailConstipation - Pipeline Review, H2 2013, Industry ReportProduct #: 113296
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved